Anxiety / depression / mood

A meta-analysis of double-blind RCTs found inositol produced marginally more responders in depression than placebo (trend, p=0.06) with a signal in PMDD, though it did not reach significance for anxiety/OCD symptoms.

In a double-blind placebo-controlled RCT, intranasal oxytocin (32 IU twice daily, 4 weeks) added to usual inpatient care produced greater reductions in depression and general distress, with a secondary analysis showing benefit concentrated in female patients.

In a large Australian pharmacoepidemiologic study, exposure to GLP-1 receptor agonists including semaglutide was associated with increased subsequent dispensing of antidepressants (adjusted HR 1.19), raising a mood-safety signal that requires vigilance.

Selank shows benzodiazepine-comparable anxiolytic activity in rat models and modulates GABA receptors, and it is described in the literature as a GABAergic agent indicated for anxiety.

PE-22-28 potently inhibits the TREK-1 channel and, in mouse behavioural despair and novelty-suppressed-feeding models, reduces immobility and feeding latency while promoting neurogenesis and synaptogenesis, supporting antidepressant activity.

In rat models Semax normalized anxiety- and depression-like behaviour and brain monoamine levels induced by cholecystokinin-tetrapeptide or neonatal SSRI exposure, indicating anxiolytic and antidepressant activity under elevated-stress conditions.